Does Aetna Cover Weight Loss Treatment in Delaware? A 2026 Guide

Last updated: July 23, 2026

If you are an Aetna member in Delaware wondering whether your plan may cover weight loss treatment, including GLP-1 medications like Wegovy or Zepbound, this guide explains what Aetna typically offers, how CVS/Caremark (Aetna’s pharmacy benefit manager) structures its weight loss formulary in 2026, and what Delaware law does and does not require insurers to cover.

Coverage varies widely by plan. Always verify your specific benefits before booking an appointment or filling a prescription.

Ready to explore weight loss treatment? Klarity Health connects you with licensed providers who can evaluate your options and discuss what may fit your health goals. See if you may qualify →

Key Facts at a Glance

Insurer: Aetna (Delaware commercial plans)
Pharmacy Benefit Manager (PBM): CVS/Caremark
State parity law: Del. Code Ann. tit. 18, § 3343. Applies to mental health and substance use disorder benefits only; does not govern weight loss coverage
Governing framework: ACA Essential Health Benefits (EHB) standards + individual plan design
Zepbound (tirzepatide): Reinstated on the CVS/Caremark formulary effective October 1, 2026 (after a July 1, 2025 removal). This is a key 2026 development for Aetna members
Delaware EPCS: Phentermine and Qsymia (Schedule IV) require electronic prescribing; GLP-1s, Contrave, and orlistat are non-scheduled (EPCS entirely inapplicable)
Medicare GLP-1 Bridge: Not applicable to Aetna commercial plans in Delaware (Humana Medicare Advantage only)
Aetna Member Services: 1-800-872-3862
CVS/Caremark Pharmacy: 1-800-552-8159
DE Department of Insurance: 1-302-674-7300

Does Delaware State Law Require Weight Loss Coverage?

Delaware’s primary insurance parity statute, Del. Code Ann. tit. 18, § 3343, aligns with the federal Mental Health Parity and Addiction Equity Act (MHPAEA). It requires that mental health and substance use disorder benefits be provided at parity with medical and surgical benefits. Section 3343 does not govern weight loss coverage. Weight management is not classified as a mental health or substance use disorder benefit under Delaware or federal parity law.

Weight loss medication coverage for Aetna commercial plans in Delaware is instead governed by:

• Federal ACA preventive care mandate: Plans must cover BMI screening and intensive behavioral counseling for obesity (USPSTF Grade B) at no cost-sharing. This covers counseling, not medications.
• Plan design and employer contract: Whether prescription weight loss medications are covered, and at what cost-sharing level, depends on your specific Aetna plan and employer elections.
• ACA Essential Health Benefits (EHB): EHB standards do not mandate coverage of weight loss drugs for marketplace plans in Delaware.

If your employer offers a self-funded ERISA plan administered by Aetna, the plan is governed by federal ERISA rules, not Delaware insurance law. Self-funded plans set their own pharmacy benefit terms. For ERISA plan questions, the U.S. Department of Labor EBSA can be reached at 1-866-444-3272.

Delaware Electronic Prescribing Requirements for Weight Loss Medications

Delaware requires electronic prescribing of controlled substances (EPCS) under Delaware Board of Medical Licensure rules and DE Admin Code Title 24 § 1700 for controlled substances in applicable schedules. Whether this applies to a specific weight loss medication depends on its federal controlled substance schedule:

Because GLP-1 medications (Wegovy, Zepbound, Saxenda) and Contrave are non-scheduled, Delaware’s EPCS requirement does not apply to them. Phentermine and Qsymia are Schedule IV controlled substances. Prescribers in Delaware must use an electronic prescribing system that meets DEA requirements to issue these prescriptions.

Qsymia also requires enrollment in the Qsymia REMS program due to teratogenicity risk, regardless of EPCS status.

Major 2026 Update: Zepbound Reinstated on CVS/Caremark (October 1, 2026)

One of the most important formulary changes for Aetna members in 2026 is the reinstatement of Zepbound (tirzepatide) on the CVS/Caremark formulary effective October 1, 2026. CVS/Caremark had removed Zepbound from many formularies effective July 1, 2025. That removal created a multi-month access gap for patients whose Aetna plans used Caremark pharmacy benefits.

As of the October 1, 2026 reinstatement, Zepbound may again be available as a covered option (typically Tier 3. 4 specialty with prior authorization) on many CVS/Caremark formularies that Aetna uses. Exact tier placement, quantity limits, and PA criteria still vary by plan. Members should confirm their specific formulary status with CVS/Caremark at 1-800-552-8159 or through the Aetna member portal.

How this differs from Express Scripts (ESI) plans: Plans that use Express Scripts as the PBM (for example, many Highmark BCBS DE and Cigna plans) generally did not remove Zepbound during the 2025. 2026 period. On ESI, Zepbound has typically remained available at Tier 3. 4 with PA. If you are comparing Aetna to Highmark or Cigna in Delaware, the Caremark removal-and-reinstatement cycle is a plan-specific detail that can affect mid-year access.

CVS/Caremark Weight Loss Formulary for Aetna Members (2026)

Aetna uses CVS/Caremark as its pharmacy benefit manager. The table below reflects how CVS/Caremark typically approaches common weight loss medications in 2026. Specific tier placement and prior authorization criteria may vary by your Aetna plan:

Ozempic and Mounjaro are FDA-approved for type 2 diabetes. Plans often deny coverage when the sole documented indication is weight loss. Wegovy and Zepbound are the weight-management formulary entries on most CVS/Caremark lists after the October 1, 2026 reinstatement.

Typical Prior Authorization Criteria for GLP-1 Weight Loss Medications

When Aetna/CVS/Caremark requires prior authorization for Wegovy, Zepbound, or Saxenda, criteria commonly include:

1. BMI threshold: BMI of 30 or higher (obesity), or BMI of 27 or higher with at least one weight-related comorbidity (for example, hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea).
2. Lifestyle documentation: Evidence of a reduced-calorie diet and increased physical activity, often for a defined lookback period.
3. Prescriber attestation: A licensed clinician documents medical necessity and the treatment plan.
4. Step therapy (plan-dependent): Some plans prefer a trial of a lower-cost agent before a specialty GLP-1.
5. Renewal criteria: Continued coverage often requires documented weight loss response (for example, a percentage of baseline body weight) within a defined timeframe.

Criteria are plan-specific. Always request the current PA form and clinical policy from Aetna or CVS/Caremark for your member ID.

How to Start a Prior Authorization with Aetna / CVS/Caremark

1. Confirm formulary status for your exact plan using the Aetna member portal or by calling CVS/Caremark at 1-800-552-8159.
2. Ask your clinician to complete the PA request with BMI, comorbidities, prior lifestyle interventions, and the specific medication requested.
3. Submit supporting records (chart notes, labs, comorbidity diagnoses) with the PA package.
4. Track the decision window and request peer-to-peer review if the initial decision is a denial based on incomplete clinical detail.
5. If denied, request a written denial letter stating the clinical policy cited, then proceed to internal appeal (see below).

Telehealth Weight Loss Care and Delaware EPCS

Telehealth can be a practical path for evaluation, lifestyle counseling, and non-controlled weight loss prescriptions. For GLP-1s, Contrave, and orlistat, Delaware EPCS rules do not apply because those agents are non-scheduled. For phentermine or Qsymia, Delaware EPCS requirements apply: the prescribing clinician must use a compliant electronic prescribing workflow, even when the visit itself is virtual.

Klarity Health’s network of 2,000+ licensed providers can evaluate whether medication-assisted weight management may be appropriate and help coordinate documentation that plans often require for prior authorization.

See if you may qualify for weight loss treatment →

If Your Plan Excludes Weight Loss Medications

Some employer-sponsored and fully insured designs exclude anti-obesity medications entirely or limit coverage to behavioral counseling only. If your Summary of Benefits and Coverage (SBC) or formulary shows an exclusion:

• Ask HR or the plan administrator whether a buy-up or rider is available at open enrollment.
• Confirm whether diabetes-indicated GLP-1s (Ozempic/Mounjaro) apply if you have a qualifying diabetes diagnosis (this is not a workaround for weight-loss-only use).
• Review manufacturer savings programs and patient assistance options, which are separate from insurance coverage and have their own eligibility rules.
• For self-funded ERISA plans, contact DOL EBSA at 1-866-444-3272 for questions about plan disclosure and claims procedures.

The Medicare GLP-1 Bridge program ($50/month Wegovy/Zepbound/Foundayo via CMS as of July 1, 2026) applies to eligible Medicare Advantage Prescription Drug members. It is not available through Aetna commercial plans in Delaware. That program is primarily relevant to Humana MA members and similar MAPD products.

Appealing an Aetna Weight Loss Coverage Denial in Delaware

1. Internal appeal: Follow the process and deadlines in your denial letter. Submit clinical notes, BMI history, comorbidity documentation, and the cited medical policy with a point-by-point response.
2. Peer-to-peer review: Request a clinician-to-clinician discussion before or during the internal appeal when the denial is medical-necessity based.
3. External review: For fully insured Delaware plans, you may request external review through the Delaware Department of Insurance after exhausting internal remedies. Contact DE DOI at 1-302-674-7300.
4. ERISA pathway (self-funded): Self-funded plans follow federal ERISA claims and appeals rules. DOL EBSA: 1-866-444-3272.
5. CMS (Medicare only): If you somehow hold a Medicare product through another carrier, CMS beneficiary resources are at 1-800-633-4227. Aetna commercial DE members use Aetna/DE DOI/ERISA paths above, not the Medicare GLP-1 Bridge.

Note: Because § 3343 is an MH/SUD parity statute, a parity complaint under § 3343 is generally not the correct pathway for a pure weight loss medication denial. Use the medical-necessity and plan-design appeal channels instead.

How to Verify Your Aetna Weight Loss Benefits (Checklist)

1. Log in to the Aetna member portal and download your current formulary and SBC.
2. Search for Wegovy, Zepbound, Saxenda, Contrave, phentermine, and Qsymia by name.
3. Call CVS/Caremark at 1-800-552-8159 with your member ID and ask for tier, PA, quantity limits, and specialty pharmacy requirements.
4. Call Aetna Member Services at 1-800-872-3862 to confirm medical benefit coverage for obesity counseling and any bariatric pathway benefits.
5. Ask your clinician to document BMI, comorbidities, and prior lifestyle interventions before submitting PA.

How Klarity Health Can Help Delaware Aetna Members

Klarity Health connects Delaware residents with licensed providers for telehealth weight management evaluations. Our network of 2,000+ providers can discuss whether GLP-1 therapy or other options may fit your clinical profile, outline documentation that CVS/Caremark often requests for prior authorization, and coordinate follow-up. Coverage is never guaranteed; your Aetna plan’s formulary and PA rules control final payment decisions.

Check if You May Qualify for Weight Loss Treatment

Frequently Asked Questions

Does Aetna cover Wegovy in Delaware?

Many Aetna commercial plans that use CVS/Caremark may cover Wegovy as a specialty medication with prior authorization when BMI and clinical criteria are met. Coverage is plan-specific. Verify on your formulary or with CVS/Caremark at 1-800-552-8159.

Is Zepbound covered by Aetna in 2026?

Zepbound was removed from many CVS/Caremark formularies on July 1, 2025, and reinstated effective October 1, 2026. After reinstatement, many Aetna plans may again list Zepbound at a specialty tier with PA. Confirm your plan’s post. October 1, 2026 status before starting therapy.

Does Delaware’s parity law force Aetna to cover weight loss drugs?

No. Del. Code Ann. tit. 18, § 3343 addresses mental health and substance use disorder parity. It does not require coverage of anti-obesity medications. Weight loss benefits follow plan design and ACA EHB rules, not § 3343.

Do I need EPCS for Wegovy or Zepbound in Delaware?

No. Wegovy and Zepbound are non-scheduled. Delaware EPCS requirements apply to controlled substances such as phentermine and Qsymia (Schedule IV), not to GLP-1 weight loss injectables.

Can I get the Medicare GLP-1 Bridge through Aetna in Delaware?

No. The Medicare GLP-1 Bridge ($50/month Wegovy/Zepbound/Foundayo via CMS as of July 1, 2026) is a Medicare Advantage. Oriented program. Aetna commercial members in Delaware should use their commercial formulary and PA process instead.

What if my employer plan excludes all weight loss drugs?

Exclusions are common on some self-funded and fully insured designs. Review your SBC, ask HR about riders at open enrollment, and discuss non-covered cash-pay or manufacturer programs with your clinician. ERISA plan participants can contact DOL EBSA at 1-866-444-3272 for process questions.

Key Contacts

• Aetna Member Services: 1-800-872-3862
• CVS/Caremark Pharmacy: 1-800-552-8159
• Delaware Department of Insurance: 1-302-674-7300
• U.S. Department of Labor EBSA (ERISA): 1-866-444-3272
• CMS (Medicare beneficiaries): 1-800-633-4227

Disclaimer

This article is for general educational purposes only and does not constitute medical, legal, or insurance advice. Insurance coverage varies by plan, employer contract, formulary year, and clinical criteria. Prior authorization requirements, tiers, and exclusions change. Always verify your benefits directly with Aetna and CVS/Caremark before starting treatment. Klarity Health does not guarantee insurance coverage or prior authorization approval. Medication decisions should be made with a licensed clinician who can evaluate your individual medical history.